

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH GROUP INC.

(中國醫療集團有限公司)

(Carrying on business in Hong Kong as “萬全醫療集團”)
(Formerly known as “Venturepharm Laboratories Limited”)
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 08225)

CESSATION OF THE APPOINTMENT OF JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of China Health Group Inc. (the “**Company**”) announces the following changes of the joint company secretaries (the “**JCSs**”) of the Company with effect from 3 June 2016:

- i. As the Company considers that joint company secretaries will not be necessary for the company business at the time being, Ms. Jing Xu (“**Ms. Xu**”) has ceased to be a JCS on 3 June 2016.
- ii. Mr. Leung Kwok Fai Ben Rich (“**Mr. Leung**”) remains the sole company secretary and the authorised representative of the Company under the rules governing the listing of securities on the Growth Enterprise Market of the Stock Exchange since 17 September 2009.

The Board would like to express its gratitude to Ms. Xu for her contributions to the Company.

By order of the Board
China Health Group Inc.
William Xia Guo
Chairman

Hong Kong, 3 June 2016

As at the date hereof, the Board comprises two executive directors, being Mr. William Xia Guo and Dr. Maria Xue Mei Song; one non-executive director, being Mr. Michael Su; and three independent non-executive directors, being Mr. Shou Yuan Wu, Dr. Bin Hui Ni and Mr. Mark Gavin Lotter.